ALMINOPROFEN

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H17NO2
Molecular Weight	219.2796
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C(O)=O)C1=CC=C(NCC(C)=C)C=C1

InChI

InChIKey=FPHLBGOJWPEVME-UHFFFAOYSA-N

InChI=1S/C13H17NO2/c1-9(2)8-14-12-6-4-11(5-7-12)10(3)13(15)16/h4-7,10,14H,1,8H2,2-3H3,(H,15,16)

HIDE SMILES / InChI

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9933032
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/2787705

Alminoprofen is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylpropionic acid class. It has anti-inflammatory properties different from the classical NSAID. Alminoprofen possesses both antiphospholipase A2 (PLA2) activity and anti-cycloxygenase (COX) activity.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cyclooxygenase-2 201 Target ID: CHEMBL230 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9933032	Inhibitor 8504
Secretory phospholipase A2, Homo sapiens 3 Target ID: Secretory phospholipase A2, Homo sapiens Sources: http://www.ncbi.nlm.nih.gov/pubmed/9933032	Inhibitor 8504
Cyclooxygenase-1 131 Target ID: CHEMBL221 Sources: http://www.genome.jp/dbget-bin/www_bget?D01513	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 619 Sources: http://www.ndrugs.com/?s=minalfen	Palliative		Approved 8583	Minalfen Approved Use Indications: inflammation, pain
Inflammation 105 Sources: http://www.ndrugs.com/?s=minalfen	Primary		Approved 8583	Minalfen Approved Use Indications: inflammation, pain

C_max

Value	Dose	Analyte	Population
24.2 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573683/	300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ALMINOPROFEN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
9.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573683/	300 mg 3 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ALMINOPROFEN unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
39.2 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7439265/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	ALMINOPROFEN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED
16.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1491485/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ALMINOPROFEN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
21.6 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1491485/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ALMINOPROFEN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
58.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1491485/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		ALMINOPROFEN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
58.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1491485/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		ALMINOPROFEN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
2.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7439265/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	ALMINOPROFEN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED
2.45 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1491485/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ALMINOPROFEN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2.49 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1491485/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ALMINOPROFEN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
300 mg 3 times / day multiple, oral Recommended Dose: 300 mg, 3 times / day Route: oral Route: multiple Dose: 300 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8573683/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8573683/	Sources: https://pubmed.ncbi.nlm.nih.gov/8573683/

PubMed

Title	Date	PubMed
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010-12	21818443

Patents

Sample Use Guides

In Vivo Use Guide

In rheumatoid arthritis and spondylosis deformans - 200 mg (three times a day) repeated dose for 5 days.

Route of Administration: Oral

In Vitro Use Guide

Alminoprofen (10(-6)-10(-4) M) inhibited dose-dependently the chemotaxis of leukocytes induced by chemotactic factors from guinea pig neutrophils stimulated with sodium urate crystals.

Name

Type

Language

ALMINOPROFEN

Official Name

English

MINALFEN

Preferred Name

English

ALMINOPROFEN [MI]

Common Name

English

alminoprofen [INN]

Common Name

English

P-((2-METHYLALLYL)AMINO)HYDRATROPIC ACID

Common Name

English

ALMINOPROFEN [MART.]

Common Name

English

Alminoprofen [WHO-DD]

Common Name

English

ALMINOPROFEN [JAN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QM01AE16